Grey Fox Wealth Advisors LLC Reduces Stock Holdings in Stryker Co. (NYSE:SYK)

Grey Fox Wealth Advisors LLC decreased its position in Stryker Co. (NYSE:SYK) by 4.4% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,593 shares of the medical technology company’s stock after selling 73 shares during the period. Grey Fox Wealth Advisors LLC’s holdings in Stryker were worth $577,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of the company. DGS Capital Management LLC purchased a new stake in shares of Stryker during the first quarter worth $239,000. Wealthcare Advisory Partners LLC lifted its position in shares of Stryker by 41.4% during the first quarter. Wealthcare Advisory Partners LLC now owns 1,049 shares of the medical technology company’s stock worth $375,000 after acquiring an additional 307 shares in the last quarter. Stokes Capital Advisors LLC lifted its position in shares of Stryker by 1.0% during the first quarter. Stokes Capital Advisors LLC now owns 26,388 shares of the medical technology company’s stock worth $9,443,000 after acquiring an additional 261 shares in the last quarter. Courier Capital LLC lifted its position in shares of Stryker by 19.3% during the first quarter. Courier Capital LLC now owns 3,357 shares of the medical technology company’s stock worth $1,201,000 after acquiring an additional 543 shares in the last quarter. Finally, Indiana Trust & Investment Management CO lifted its position in shares of Stryker by 26.7% during the first quarter. Indiana Trust & Investment Management CO now owns 4,251 shares of the medical technology company’s stock worth $1,521,000 after acquiring an additional 895 shares in the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Stock Down 0.8 %

Shares of NYSE:SYK opened at $363.24 on Thursday. The stock’s 50-day moving average price is $357.99 and its 200-day moving average price is $343.59. Stryker Co. has a 12-month low of $255.22 and a 12-month high of $374.63. The stock has a market capitalization of $138.42 billion, a P/E ratio of 40.49, a price-to-earnings-growth ratio of 2.83 and a beta of 0.91. The company has a current ratio of 1.68, a quick ratio of 0.95 and a debt-to-equity ratio of 0.51.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Tuesday, July 30th. The medical technology company reported $2.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.79 by $0.02. Stryker had a return on equity of 22.89% and a net margin of 16.12%. The firm had revenue of $5.42 billion for the quarter, compared to analysts’ expectations of $5.40 billion. During the same period last year, the firm earned $2.54 earnings per share. The company’s revenue for the quarter was up 8.5% compared to the same quarter last year. On average, equities analysts anticipate that Stryker Co. will post 12 earnings per share for the current year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 31st. Stockholders of record on Monday, September 30th will be paid a dividend of $0.80 per share. The ex-dividend date of this dividend is Monday, September 30th. This represents a $3.20 dividend on an annualized basis and a dividend yield of 0.88%. Stryker’s dividend payout ratio (DPR) is currently 35.67%.

Wall Street Analysts Forecast Growth

SYK has been the topic of several recent research reports. Truist Financial increased their target price on Stryker from $345.00 to $370.00 and gave the stock a “hold” rating in a research report on Monday, October 14th. Wolfe Research began coverage on Stryker in a research report on Tuesday, September 10th. They issued an “outperform” rating and a $405.00 price objective on the stock. BTIG Research increased their price objective on Stryker from $374.00 to $383.00 and gave the stock a “buy” rating in a research report on Monday, October 14th. StockNews.com upgraded Stryker from a “hold” rating to a “buy” rating in a research report on Tuesday, October 1st. Finally, Morgan Stanley increased their price objective on Stryker from $345.00 to $350.00 and gave the stock an “equal weight” rating in a research report on Monday, July 15th. Four investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $381.16.

Insider Activity

In other news, CFO Glenn S. Boehnlein sold 20,000 shares of the firm’s stock in a transaction dated Friday, August 2nd. The stock was sold at an average price of $333.00, for a total transaction of $6,660,000.00. Following the transaction, the chief financial officer now directly owns 2,852 shares of the company’s stock, valued at approximately $949,716. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, CFO Glenn S. Boehnlein sold 20,000 shares of the firm’s stock in a transaction dated Friday, August 2nd. The stock was sold at an average price of $333.00, for a total value of $6,660,000.00. Following the sale, the chief financial officer now directly owns 2,852 shares of the company’s stock, valued at $949,716. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Viju Menon sold 600 shares of the firm’s stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $355.00, for a total value of $213,000.00. Following the completion of the sale, the insider now directly owns 9,069 shares in the company, valued at $3,219,495. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 220,068 shares of company stock valued at $71,811,372. 5.90% of the stock is currently owned by insiders.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.